BioTelemetry (NASDAQ:BEAT) will be announcing its earnings results after the market closes on Tuesday, February 20th. Analysts expect the company to announce earnings of $0.23 per share for the quarter.
Shares of BioTelemetry (NASDAQ:BEAT) opened at $32.55 on Tuesday. The stock has a market capitalization of $1,030.00, a P/E ratio of 24.85, a PEG ratio of 1.41 and a beta of 0.67. BioTelemetry has a one year low of $23.30 and a one year high of $39.20. The company has a quick ratio of 1.48, a current ratio of 1.60 and a debt-to-equity ratio of 0.75.
Several equities research analysts have recently issued reports on BEAT shares. Raymond James Financial started coverage on BioTelemetry in a research note on Thursday, October 26th. They issued an “outperform” rating and a $37.00 price objective for the company. SunTrust Banks started coverage on BioTelemetry in a research note on Monday, October 23rd. They issued a “buy” rating and a $41.00 price objective for the company. Zacks Investment Research lowered BioTelemetry from a “hold” rating to a “strong sell” rating in a research note on Thursday, November 2nd. Dougherty & Co reissued a “buy” rating and set a $40.00 price target on shares of BioTelemetry in a research note on Wednesday, November 8th. Finally, BidaskClub raised BioTelemetry from a “sell” rating to a “hold” rating in a research note on Wednesday, December 27th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $42.86.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/13/biotelemetry-beat-set-to-announce-quarterly-earnings-on-tuesday.html.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.